Does aspirin really reduce the risk of colon cancer?

The Lancet

Volumn 379, Issue 9826, 2012, Pages 1586-

  Cleland, John G F ^a  

^a UNIVERSITY OF HULL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT;

CANCER RISK; COLON CANCER; FOLLOW UP; HEART INFARCTION; HUMAN; LETTER; OUTCOME ASSESSMENT; PRIORITY JOURNAL; STROKE; HEREDITARY NONPOLYPOSIS COLORECTAL CANCER; HETEROZYGOTE; NOTE;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; COLORECTAL NEOPLASMS, HEREDITARY NONPOLYPOSIS; HETEROZYGOTE; HUMANS;

EID: 84860291337     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(12)60671-0     Document Type: Letter

References (5)

1. Burn J, Gerdes AM, Macrae F, et al, on behalf of the CAPP2 Investigators. Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial. Lancet 2011; 378: 2081-87.
2. Chan AT, Lippman SM. Aspirin and colorectal cancer prevention in Lynch syndrome. Lancet 2011; 378: 2051-52.
3. Burn J, Bishop DT, Mecklin JP, et al. Effect of aspirin or resistant starch on colorectal neoplasia in the Lynch syndrome. N Engl J Med 2008; 359: 2567-78.
4. Baron JA, Cole BF, Sandler RS, et al. A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med 2003; 348: 891-99.
5. Cleland JG. Aspirin in the primary prevention of vascular disease. Lancet 2009; 374: 878.